Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model

O. Titova (St. Petersburg, Russian Federation), N. Kuzubova (St. Petersburg, Russian Federation), E. Lebedeva (St. Petersburg, Russian Federation), E. Volchkova (St. Petersburg, Russian Federation)

Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Titova (St. Petersburg, Russian Federation), N. Kuzubova (St. Petersburg, Russian Federation), E. Lebedeva (St. Petersburg, Russian Federation), E. Volchkova (St. Petersburg, Russian Federation). Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model. 735

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015



Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Year: 2018




Protective effect of inhaled glucocorticosteroids on COPD model.
Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair
Year: 2020


Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids
Source: Eur Respir J 2016; 48: 558-560
Year: 2016


The effect of inhaled corticosteroids in combination with long-acting beta2-agonists in elite athletes with asthma
Source: Annual Congress 2009 - Asthma and comorbid conditions
Year: 2009

Effect of long-acting ß-agonist on bronchodilator response in children with asthma
Source: Eur Respir J, 56 (3) 1902010; 10.1183/13993003.02010-2019
Year: 2020



Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007


The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

The anti-tussive effects of an inhaled LABA are maintained after chronic treatment
Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Year: 2018



Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD
Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018
Year: 2019



Effects of montelukast on tapering inhaled corticosteroids in patients with asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 260s
Year: 2001

Effects of montelukast on tapering inhaled corticosteroids in patients with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 407s
Year: 2002

Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006

Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta2-agonist on FeNO in asthmatic children on regular inhaled budesonide
Source: Eur Respir J 2002; 20: Suppl. 38, 431s
Year: 2002

Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008


Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma
Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019
Year: 2020